•
Jun 30, 2022
Nuvation Bio Q2 2022 Earnings Report
Nuvation Bio reported financial results for the second quarter ended June 30, 2022 and provided a business update.
Key Takeaways
Nuvation Bio reported a net loss of $34.9 million, or $0.16 per share, for the three months ended June 30, 2022. The company's cash, cash equivalents and marketable securities totaled $703.8 million as of June 30, 2022.
Dosing is underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors.
The company has a strong financial position with cash runway through 2028.
Cash, cash equivalents and marketable securities totaled $703.8 million as of June 30, 2022.
David Liu, M.D., Ph.D., was appointed as Chief Medical Officer in July 2022, and Kerry Wentworth as Chief Regulatory Officer in May 2022.